Vivani Medical Bets on Implantable Semaglutide for Lasting Weight Loss

Vivani Medical is racing to develop a miniature implantable device loaded with semaglutide — the active ingredient powering Novo Nordisk's blockbuster obesity drug Wegovy and its diabetes sibling Ozempic — in a bid to help patients sustain weight loss without weekly injections or daily pills.

The implant represents one of the most ambitious attempts yet to address a well-documented challenge in GLP-1 therapy: patient adherence. Studies and market data have consistently shown that a large share of people discontinue injectable weight-loss medications within the first year, erasing much of the metabolic progress they achieved while on treatment.

Read more Apple Sues OpenAI Over Trade Secret Theft, Sparking Tech Backlash →

By delivering semaglutide continuously from beneath the skin, Vivani's device could theoretically remove the burden of self-injection schedules and reduce the risk of missed doses — a structural fix rather than a behavioral one. The approach mirrors strategies already used in long-acting contraceptive implants and certain psychiatric medications, applying proven drug-delivery architecture to the fast-growing obesity market.

The GLP-1 sector has attracted enormous pharmaceutical and investor interest as Wegovy and Ozempic transformed Novo Nordisk into one of Europe's most valuable companies. Startups and established players alike are now competing to extend, improve, or differentiate around semaglutide's core mechanism, and Vivani's implant adds a hardware dimension to that race.

Whether the device can clear regulatory hurdles, demonstrate sustained efficacy, and win patient acceptance remains to be seen, but its development signals that the next frontier of weight-loss medicine may be as much about delivery innovation as drug discovery. Continue reading at US Top News and Analysis.